About H1N1 vaccine, H1N1vaccine production, H1N1 vaccine manufacturers

Surgical Adhesive. CE Mark approval allows TissuGlu to be sold in the European Union.

TissuGlu is an internal surgical adhesive for large flap surgeries, such as abdominoplasties, that helps reduce fluid accumulation and the need for postsurgical drains.  Its unique chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may provide the patient with a quicker return to normal activity.

“TissuGlu Surgical Adhesive provides an innovative approach to the way plastic surgeons address wound drainage challenges and helps plastic surgeons improve the overall care of their patients,” said Dr. Peter Rubin, Chief, Division of Plastic and Reconstructive Surgery at the University of Pittsburgh Medical Center. “Surgeons will be keen to apply this product to their procedures, which we believe will ultimately save them time and money through the reduction of post-surgical complications and additional OR time.”

TissuGlu will be commercially available in Germany in the third quarter of 2011.  Cohera Medical is also actively pursuing U.S. FDA approval.

“CE Mark approval moves Cohera from an early-stage company to a commercial entity,” said Patrick Daly, President and Chief Executive Officer of Cohera Medical. “We look forward to beginning our commercialization in Germany, a strategic market, which we believe will demonstrate commercial viability for TissuGlu Surgical Adhesive and serve as a springboard for expansion across the EU and to other vital markets, including the US.”

Continued on Next page >> Related postsMen and women with stretch marks problem can benefit from laser treatmentMen and women of all sizes are plagued with dreaded stretch marks and the process of eliminating the…Vote For Kids Health calls for voting support to help win December Pepsi Refresh ProjectCritically ill and disadvantaged children are counting on the generosity of strangers Thursday, Dece…Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myelomaOnyx Pharmaceuticals, Inc. today announced results from an ongoing Phase 2 study, known as the 004 s…Women persist in plastic surgery treatments that are not workingWomen are more likely to persist with using creams, supplements and plastic surgery to look younger … Comments The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net. Cancel answer to comment

Quirky Comment Title
Name

View the Original article

Related posts:

1. Lucentis receives Health Canada approval to treat vision loss from DME
2. DiscoveryBioMed receives NIDDK grant for Cystic Fibrosis Corrector Ligand Drug Discovery program
3. UMA introduces new healthcare education and career resource center
4. Teen milk drinkers less likely to suffer from Type 2 diabetes
5. Novo Nordisk announces free diabetes educational e-book series